دورية أكاديمية
Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.
| العنوان: | Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls. |
|---|---|
| المؤلفون: | Agalliu I; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA., Ortega RA; Department of Neurology, Mount Sinai Beth Israel Medical Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Luciano MS; Department of Neurology, University of California San Francisco, San Francisco, California, USA., Mirelman A; Movement Disorders Unit, Department of Neurology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel., Pont-Sunyer C; Neurology Service, Hospital Clínic, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Universitat de Barcelona, Catalonia, Spain.; Neurology Unit, Hospital General de Granollers, Universitat Internacional de Catalunya, Granollers, Barcelona, Spain., Brockmann K; Hertie-Institut für klinische Hirnforschung, Tubingen, Germany., Vilas D; Neurology Service, Hospital Clínic, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Universitat de Barcelona, Catalonia, Spain.; Movement Disorders Unit, Neurology Service, Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain., Tolosa E; Neurology Service, Hospital Clínic, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Universitat de Barcelona, Catalonia, Spain., Berg D; Hertie-Institut für klinische Hirnforschung, Tubingen, Germany.; Department of Neurology, Christian-Albrechts-University, Kiel, Germany., Warø B; Department of Neurology, St. Olavs Hospital, and Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway., Glickman A; Department of Neurology, Mount Sinai Beth Israel Medical Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Raymond D; Department of Neurology, Mount Sinai Beth Israel Medical Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Inzelberg R; Department of Neurology and Neurosurgery, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Ruiz-Martinez J; Neurology Department, Donostia University Hospital, Biodonostia Institut Research, Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas, San Sebastian, Gipuzkoa, Spain., Mondragon E; Neurology Department, Donostia University Hospital, Biodonostia Institut Research, Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas, San Sebastian, Gipuzkoa, Spain., Friedman E; The Susanne Levy Gertner Oncogenetics Unit, Institute of Human Genetics, Sheba Medical Center, Tel-Hashomer and the Departments of Internal Medicine and Genetics and Biochemistry, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel., Hassin-Baer S; Department of Neurology and Neurosurgery, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Parkinson's Disease and Movement Disorders Clinic and Department of Neurology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel., Alcalay RN; Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA., Mejia-Santana H; Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA., Aasly J; Department of Neurology, St. Olavs Hospital, and Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway., Foroud T; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA., Marder K; Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA., Giladi N; Movement Disorders Unit, Department of Neurology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel., Bressman S; Department of Neurology, Mount Sinai Beth Israel Medical Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Saunders-Pullman R; Department of Neurology, Mount Sinai Beth Israel Medical Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA. |
| المصدر: | Movement disorders : official journal of the Movement Disorder Society [Mov Disord] 2019 Sep; Vol. 34 (9), pp. 1392-1398. Date of Electronic Publication: 2019 Jul 26. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8610688 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-8257 (Electronic) Linking ISSN: 08853185 NLM ISO Abbreviation: Mov Disord Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2001->: New York, NY : Wiley-Liss Original Publication: [New York, N.Y.] : Raven Press, [c1986- |
| مواضيع طبية MeSH: | Leucine-Rich Repeat Serine-Threonine Protein Kinase-2/*genetics , Neoplasms/*complications , Neoplasms/*therapy , Parkinson Disease/*complications , Parkinson Disease/*genetics, Aged ; Aged, 80 and over ; Colonic Neoplasms/epidemiology ; Colonic Neoplasms/genetics ; Female ; Humans ; Male ; Middle Aged ; Mutation/genetics ; Neoplasms/epidemiology ; Prevalence ; Risk ; Skin Neoplasms/epidemiology ; Skin Neoplasms/genetics ; Treatment Outcome |
| مستخلص: | Background: Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison with idiopathic PD (IPD). It is unclear whether the elevated risk would be maintained when compared with unaffected controls. Methods: Cancer outcomes were compared among 257 LRRK2-PD patients, 712 IPD patients, and 218 controls recruited from 7 LRRK2 consortium centers using mixed-effects logistic regression. Data were then pooled with a previous study to examine cancer risk between 401 LRRK2-PD and 1946 IPD patients. Results: Although cancer prevalence was similar among LRRK2-PD patients (32.3%), IPD patients (27.5%), and controls (27.5%; P = 0.33), LRRK2-PD had increased risks of leukemia (odds ratio [OR] = 4.55; 95% confidence interval [CI], 1.46-10.61) and skin cancer (OR = 1.61; 95% CI, 1.09-2.37). In the pooled analysis, LRRK2-PD patients had also elevated risks of leukemia (OR = 9.84; 95% CI, 2.15-44.94) and colon cancer (OR = 2.34; 95% CI, 1.15-4.74) when compared with IPD patients. Conclusions: The increased risks of leukemia as well as skin and colon cancers among LRRK2-PD patients suggest that LRRK2 mutations heighten risks of certain cancers. © 2019 International Parkinson and Movement Disorder Society. (© 2019 International Parkinson and Movement Disorder Society.) |
| References: | Brain Behav. 2017 Dec 07;8(1):e00858. (PMID: 29568677) Mov Disord. 2010 Nov 15;25(15):2536-41. (PMID: 20818610) JAMA Neurol. 2015 Jan;72(1):58-65. (PMID: 25401981) Parkinsonism Relat Disord. 2010 Mar;16(3):186-90. (PMID: 19945903) Cancer Epidemiol. 2017 Oct;50(Pt A):16-21. (PMID: 28763723) Lancet Neurol. 2008 Jul;7(7):583-90. (PMID: 18539534) J Neurol. 2013 Aug;260(8):2177-8. (PMID: 23824357) Neurology. 2009 Oct 20;73(16):1286-91. (PMID: 19841380) Trends Neurosci. 2005 Jul;28(7):348-52. (PMID: 15913799) Neurology. 2012 Mar 13;78(11):781-6. (PMID: 22323743) Fam Cancer. 2003;2(2):101-8. (PMID: 14574159) Cancer Causes Control. 2010 May;21(5):697-707. (PMID: 20054708) Nat Rev Cancer. 2011 Oct 24;11(11):812-23. (PMID: 22020207) Int J Circumpolar Health. 2019 Dec;78(1):1571383. (PMID: 30724720) Neurogenetics. 2009 Apr;10(2):157-9. (PMID: 19020907) Int J Cancer. 2012 Oct 15;131(8):1904-11. (PMID: 22278152) Mov Disord. 2014 May;29(6):750-5. (PMID: 24357540) Arch Neurol. 2012 Dec;69(12):1572-7. (PMID: 22945795) Mov Disord. 2014 Sep;29(10):1325-6. (PMID: 25048644) Neurology. 2007 Oct 9;69(15):1542-50. (PMID: 17699801) Aust N Z J Public Health. 2014 Feb;38(1):35-8. (PMID: 24494943) Mov Disord. 2011 Nov;26(13):2343-6. (PMID: 21954089) Neurology. 2011 Jun 7;76(23):2002-9. (PMID: 21646627) J Neural Transm (Vienna). 2011 Aug;118(8):1199-207. (PMID: 21298300) Ann N Y Acad Sci. 2009 Feb;1155:324-34. (PMID: 19250224) Neurology. 2008 Nov 11;71(20):1650; author reply 1650-1. (PMID: 19001259) |
| معلومات مُعتمدة: | K02 NS073836 United States NS NINDS NIH HHS; K23 NS099441 United States NS NINDS NIH HHS; U01 NS094148 United States NS NINDS NIH HHS; U01 NS100600 United States NS NINDS NIH HHS |
| فهرسة مساهمة: | Keywords: G2019S mutation; LRRK2 gene; Parkinson's disease; colon cancer; leukemia; pooled analysis |
| المشرفين على المادة: | EC 2.7.11.1 (LRRK2 protein, human) EC 2.7.11.1 (Leucine-Rich Repeat Serine-Threonine Protein Kinase-2) |
| تواريخ الأحداث: | Date Created: 20190727 Date Completed: 20200626 Latest Revision: 20200703 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC6754269 |
| DOI: | 10.1002/mds.27807 |
| PMID: | 31348549 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!